These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 22372206)

  • 1. Issues and critiques of the forthcoming risk evaluation and mitigation strategy (REMS) for opioids in pain management.
    Peppin JF; Coleman JJ; Kirsh KL
    Issues Law Med; 2011; 27(2):91-119. PubMed ID: 22372206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opioid risk management: understanding FDA mandated risk evaluation and mitigation strategies (REMS).
    Sloan PA
    J Opioid Manag; 2009; 5(3):131-3. PubMed ID: 19662921
    [No Abstract]   [Full Text] [Related]  

  • 3. Evolution of opioid risk management and review of the classwide REMS for extended-release/long-acting opioids.
    Stanos S
    Phys Sportsmed; 2012 Nov; 40(4):12-20. PubMed ID: 23306411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended-release/long-acting opioid REMS may fill the need for prescribers' appropriate use education.
    Nicholson SC; Evanyo K; Salinas GD; Roepke N; Burton BS; Susalka D
    J Opioid Manag; 2012; 8(4):212-6. PubMed ID: 22941848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk Evaluation and Mitigation Strategies (REMS) for extended-release and long-acting opioid analgesics: considerations for palliative care practice.
    Gudin J
    J Pain Palliat Care Pharmacother; 2012 Jun; 26(2):136-43. PubMed ID: 22764852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rehabilitating opioid regulation: a prescription for the FDA's next proposal of an opioid risk evaluation and mitigation strategy (REMS).
    Homenko H
    Health Matrix Clevel; 2012; 22(1):273-313. PubMed ID: 22616548
    [No Abstract]   [Full Text] [Related]  

  • 7. Shared risk evaluation mitigation strategy for all immediate-release transmucosal fentanyl dosage forms.
    Food And Drug Administration, Public Health Service, U.S. Department Of Health And Human Services
    J Pain Palliat Care Pharmacother; 2012 Jun; 26(2):123-6. PubMed ID: 22764848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Class-wide REMS for extended-release and long-acting opioids: potential impact on pharmacies.
    Matthews ML
    J Am Pharm Assoc (2003); 2013; 53(1):e1-7. PubMed ID: 23636166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. REMS; red tape, or a remedy for opioid abuse?
    Porada S
    J Fam Pract; 2011 Sep; 60(9 Suppl):S55-62. PubMed ID: 22442761
    [No Abstract]   [Full Text] [Related]  

  • 10. Primary care physician opinion survey on FDA opioid risk evaluation and mitigation strategies.
    Slevin KA; Ashburn MA
    J Opioid Manag; 2011; 7(2):109-15. PubMed ID: 21561034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Foundations of opioid risk management.
    Katz NP; Adams EH; Benneyan JC; Birnbaum HG; Budman SH; Buzzeo RW; Carr DB; Cicero TJ; Gourlay D; Inciardi JA; Joranson DE; Kesslick J; Lande SD
    Clin J Pain; 2007 Feb; 23(2):103-18. PubMed ID: 17237659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding risk evaluation and mitigation strategies in organ transplantation.
    Gabardi S
    Pharmacotherapy; 2011 Jul; 31(7):714-22. PubMed ID: 21923459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ER/LA Opioid Analgesics REMS: Overview of Ongoing Assessments of Its Progress and Its Impact on Health Outcomes.
    Cepeda MS; Coplan PM; Kopper NW; Maziere JY; Wedin GP; Wallace LE
    Pain Med; 2017 Jan; 18(1):78-85. PubMed ID: 27373304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Food and Drug Administration risk evaluation and mitigation strategy.
    Craig DS
    J Pain Palliat Care Pharmacother; 2010 Jun; 24(2):145-8. PubMed ID: 20504137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Curbing the opioid epidemic in the United States: the risk evaluation and mitigation strategy (REMS).
    Nelson LS; Perrone J
    JAMA; 2012 Aug; 308(5):457-8. PubMed ID: 22851109
    [No Abstract]   [Full Text] [Related]  

  • 16. Mitigating the safety risks of drugs with a focus on opioids: are risk evaluation and mitigation strategies the answer?
    Brooks MJ
    Mayo Clin Proc; 2014 Dec; 89(12):1673-84. PubMed ID: 25441401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in misuse and abuse of prescription opioids following implementation of Extended-Release and Long-Acting Opioid Analgesic Risk Evaluation and Mitigation Strategy.
    Bucher Bartelson B; Le Lait MC; Green JL; Cepeda MS; Coplan PM; Maziere JY; Wedin GP; Dart RC
    Pharmacoepidemiol Drug Saf; 2017 Sep; 26(9):1061-1070. PubMed ID: 28758289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (RADARS).
    Cicero TJ; Dart RC; Inciardi JA; Woody GE; Schnoll S; Muñoz A
    Pain Med; 2007 Mar; 8(2):157-70. PubMed ID: 17305687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increase your Confidence in Opioid Prescribing: Marketing Messages in Continuing Medical Education Activities on ER/LA Opioids.
    Goodwin B; Lim HD; Butler J; Paglia D; Dempsey MT; O Connor B; Fugh-Berman A
    Pain Physician; 2021 Aug; 24(5):E529-E538. PubMed ID: 34323440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Food and Drug Administration opioid Risk Evaluation and Mitigation Strategy.
    Lipman AG
    J Pain Palliat Care Pharmacother; 2009; 23(3):219-21. PubMed ID: 19670017
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.